NCT00645320View on ClinicalTrials.gov

A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2003

Study Completion Date

August 31, 2004

Conditions

Pyschotic Disorders

Interventions

DRUG

Ziprasidone

Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.

Trial Locations (8)

22640-100

Pfizer Investigational Site, RIO de Janeiro RJ

60175-270

Pfizer Investigational Site, Fortaleza

41180-000

Pfizer Investigational Site, Salvador

30150-270

Pfizer Investigational Site, Belo Horizonte

Unknown

Pfizer Investigational Site, Curitiba

Pfizer Investigational Site, Rio de Janeiro

Pfizer Investigational Site, São Paulo

40340-720

Pfizer Investigational Site, Jardim Santa Monica SN

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00645320 - A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study | Biotech Hunter | Biotech Hunter